Prevalence of acquired fosfomycin resistance among extended-spectrum  -lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3

Lee, So Young; Park, Yeon Joon; Yu, Jin Kyung; Jung, Seungwon; Kim, Yoonjoo; Jeong, Seok Hoon; Arakawa, Yoshichika

doi:10.1093/jac/dks319

Cited by 138 publications

(117 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, because the number of the isolates used in the present study was limited, further evaluation will be required to determine whether our test can be used to identify all types of FR-GST producers. Recently, it was reported that the fosA3 gene has been detected in Klebsiella pneumoniae clinical isolates (7). Future studies are required to evaluate the capability of the test developed here to detect FR-GST producers other than E. coli.…”

Section: Discussionmentioning

confidence: 97%

“…Since our first report of fosfomycin-resistant E. coli organisms producing FosA3 in 2010, reports from East Asian countries have identified many FosA3 producers in E. coli isolates from clinical specimens (7), healthy individuals (6), consumable animal products (8,9), and domestic animals (10). Further spread of the gene encoding FosA3 would be a serious public health concern because of the global distribution of CTX-M-type ESBL producers in a variety of settings (11).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Practical Agar-Based Disk Potentiation Test for Detection of Fosfomycin-Nonsusceptible Escherichia coli Clinical Isolates Producing Glutathione S -Transferases

et al. 2014

View full text Add to dashboard Cite

The number of reports concerning Escherichia coli clinical isolates that produce glutathione S-transferases responsible for fosfomycin resistance (FR-GSTs) has been increasing. We have developed a disk-based potentiation test in which FR-GST producers expand the growth inhibition zone around a Kirby-Bauer disk containing fosfomycin in combination with sodium phosphonoformate (PPF). PPF, an analog of fosfomycin, is a transition-state inhibitor of FosA PA , a type of FR-GST from Pseudomonas aeruginosa. Considering its mechanism of action, PPF was expected to inhibit a variety of FR-GSTs. In the presence of PPF, zone enlargement around the disk containing fosfomycin was observed for FosA3-, FosA4-, and FosC2-producing E. coli clinical isolates. Moreover, the growth inhibition zone was remarkably enlarged when the Mueller-Hinton (MH) agar plate contained 25 g/ml glucose-6-phosphate (G6P). When we retrospectively tested 12 fosfomycin-resistant (MIC, >256 g/ml) E. coli clinical isolates from our hospital with the potentiation test, 6 FR-GST producers were positive phenotypically by potentiation disk and were positive for FR-GST genes: 5 harbored fosA3 and 1 harbored fosA4. To identify the production of FR-GSTs, we set the provisional cutoff value, 5-mm enlargement, by adding PPF to a fosfomycin disk on the MH agar plates containing G6P. Our diskbased potentiation test reliably identifies FR-GST producers and can be performed easily; therefore, it will be advantageous in epidemiological surveys and infection control of fosfomycin-resistant bacteria in clinical settings.

show abstract

Section: Discussionmentioning

confidence: 97%

mentioning

confidence: 99%

Practical Agar-Based Disk Potentiation Test for Detection of Fosfomycin-Nonsusceptible Escherichia coli Clinical Isolates Producing Glutathione S -Transferases

et al. 2014

View full text Add to dashboard Cite

show abstract

“…New subtypes, with similar structure, of the gene have been described (fosA2, fosA3, fosA4, and fosA5) (108)(109)(110). Cooccurrence in plasmids with bla CTX-M , bla NDM , bla KPC , bla OXA , bla CMY , bla AmpC , bla TEM , bla SHV , bla SFO-1 , gyrA, parC, parE, sul1, sul2, strA, strB, aac(6=)-Ib, aadA5, aphA6, tetA(A), mphA, floR, dfrA7, rmtB, and merA genes has been reported, conferring resistance to ␤-lactams, quinolones, aminoglycosides, macrolides, sulfonamides, and tetracyclines (75,80,(111)(112)(113)(114). The genes conferring resistance to fosfomycin could be transferred together with genes conferring resistance to other antibiotics in either the same or a conjugate plasmid (114).…”

Section: Acquired Resistancementioning

confidence: 99%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

SUMMARYThe treatment of bacterial infections suffers from two major problems: spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack of development of new antibiotics active against such MDR and XDR bacteria. As a result, physicians have turned to older antibiotics, such as polymyxins, tetracyclines, and aminoglycosides. Lately, due to development of resistance to these agents, fosfomycin has gained attention, as it has remained active against both Gram-positive and Gram-negative MDR and XDR bacteria. New data of higher quality have become available, and several issues were clarified further. In this review, we summarize the available fosfomycin data regarding pharmacokinetic and pharmacodynamic properties, thein vitroactivity against susceptible and antibiotic-resistant bacteria, mechanisms of resistance and development of resistance during treatment, synergy and antagonism with other antibiotics, clinical effectiveness, and adverse events. Issues that need to be studied further are also discussed.

show abstract

“…With respect of ESBL control, Cho et al [18] tested 277 isolates of ESBL-positive E. coli and Klebsiella pneumoniae from urine samples of patients with UTI, and showed that 243 out of the 277 (87.7%) isolates were susceptible to fosfomycin. In another study, a total of 347 non-duplicate ESBL-producing E. coli (165 isolates) and K. pneumoniae (182 isolates) were collected, and the susceptibility to fosfomycin was reported to be 92.9% in E. coli and 95.2% in K. pneumoniae (Table 2) [19].…”

Section: Discussionmentioning

confidence: 99%

The Antibiotic Susceptibility of Escherichia coli from Community-Acquired Uncomplicated Urinary Tract Infection: A Focused on Fosfomycin

Choe

Lee

Chang

et al. 2017

Urogenit Tract Infect

View full text Add to dashboard Cite

Purpose:To assess the antibiotic susceptibility of Escherichia coli from community-acquired uncomplicated urinary tract infection (UTI). Materials and Methods: Between August and December of 2015, confirmed cases of E. coli as a pathogen of community-acquired uncomplicated UTI were collected and assessed for antibiotic susceptibility in 10 designated hospitals. Additional fosfomycin susceptibility test was performed by a central laboratory using the disk diffusion method. Results: A total of 347 E. coli isolates were collected from urine samples of community-acquired uncomplicated UTIs patients. The susceptibility rates of antibiotics were as follows: amikacin 100.0% (347), imipenem 100.0% (347), ciprofloxacin 57.1% (198), cefotaxime 74.9% (260), ampicillin 30.0% (104), trimethoprim/sulfamethoxazole 66.9% (232), and fosfomycin 98.0% (340). All fosfomycin-resistant E. coli isolates were extended-spectrum -lactamase (ESBL)-producing. In 85 cases of ESBL-producing E. coli, the fosfomycin susceptibility rate was 91.8% (78/85). Conclusions: Fosfomycin may be a useful option for the treatment of community-acquired uncomplicated UTIs. Further studies evaluating the role of fosfomycin in the treatment of UTIs and its clinical efficacy are necessary.

show abstract

Prevalence of acquired fosfomycin resistance among extended-spectrum -lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3

Abstract: An IS26-composite transposon appears to be the main vehicle for dissemination of fosA3 in E. coli and K. pneumoniae of diverse clones.

Cited by 138 publications

References 20 publications

Practical Agar-Based Disk Potentiation Test for Detection of Fosfomycin-Nonsusceptible Escherichia coli Clinical Isolates Producing Glutathione S -Transferases

Practical Agar-Based Disk Potentiation Test for Detection of Fosfomycin-Nonsusceptible Escherichia coli Clinical Isolates Producing Glutathione S -Transferases

Fosfomycin

The Antibiotic Susceptibility of Escherichia coli from Community-Acquired Uncomplicated Urinary Tract Infection: A Focused on Fosfomycin

Contact Info

Product

Resources

About